Evidence map›Paper›PMID 41425719›Full record

Trial reportOncology research2025

Jiunn-Wei Wang, Wen-Hung Hsu, Fang-Jung Yu, Fu-Chen Kuo, Chung-Jung Liu, Chao-Hung Kuo, Jaw-Yuan Wang, Ming-Hong Lin, Deng-Chyang Wu

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiunn-Wei WangGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807378, Taiwan.
Wen-Hung HsuDepartment of Internal Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807378, Taiwan.
Fang-Jung YuDepartment of Internal Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807378, Taiwan.
Fu-Chen KuoSchool of Medicine, College of Medicine, E-Da Hospital, I-Shou University, Kaohsiung, 84001, Taiwan.
Chung-Jung LiuDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, 80756, Taiwan.
Chao-Hung KuoGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807378, Taiwan.
Jaw-Yuan WangDepartment of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807378, Taiwan.
Ming-Hong LinDepartment of Microbiology and Immunology, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807378, Taiwan.
Deng-Chyang WuGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807378, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Colorectal adenomatous polyps frequently recur after removal and are precursors to colorectal cancer, highlighting the need for effective preventive strategies. This study evaluated the efficacy of probiotic Methods: We conducted a randomized, single-blind, two-year crossover trial in patients with a history of adenomatous polyps. Participants received CBM588 in either the first or second year, with the alternate year as observation, and underwent annual surveillance colonoscopies. Outcomes (adenoma recurrence and polyp counts) were analyzed by intention-to-treat (ITT) and per-protocol (PP) approaches. Results: A total of 398 participants were enrolled. In first-year ITT analysis, the CBM588-first group had a lower mean polyp count (0.78 vs. 1.00) and lower adenoma recurrence rate (30.00% vs. 35.35%) than the control-first group, though these differences were not statistically significant ( Conclusion: CBM588 demonstrated potential to reduce colorectal adenoma recurrence in high-risk patients, supporting its role as a feasible, non-invasive preventive strategy.

Indexed as

Adenomatous PolypsClostridium butyricumColorectal NeoplasmsNeoplasm Recurrence, LocalProbioticsAdultAgedColonoscopyCross-Over StudiesFemaleHumansMaleMiddle AgedSingle-Blind MethodTreatment Outcomeadenoma preventionClostridium butyricumcolorectal polypsGut microbiotaprobiotics

Identifiers

PMID41425719
PMCPMC12712693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.